1 completed, 1 not yet recruiting, 1 recruiting. 1 Early Phase 1, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Recurrent or Progressive Glioblastoma: new trials by email Literature Review of Recurrent or Progressive Glioblastoma trials Research Report on Recurrent or Progressive Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. CBX-663 - Advanced Solid Tumors, Recurrent or Progressive Glioblastoma | Phase 1 | Recruiting | Crossbow Therapeutics, Inc. | 120 | 2026-08-04 | 2026-10-21 |
| WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients WL276 CAR-T cells - Recurrent or Progressive Glioblastoma | Early Phase 1 | Not yet recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 6 | 2024-11-12 | 2024-11-18 |
| Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy Bevacizumab, Chemotherapy, Fractionated radiosurgery - Recurrent or Progressive Glioblastoma | Phase 3 | Completed | Henry Ford Health System | 35 | 2010-11-01 | 2023-07-17 |
Recurrence (3) · Glioblastoma (1)
Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Astrocytoma (1) · Glioma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Neuroectodermal Tumors (1)
Bevacizumab (1) · Carboplatin (1) · Drug Therapy (1) · Etoposide (1) · Temozolomide (1)
Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Crossbow Therapeutics, Inc. (1) · Henry Ford Health System (1)
United States (2)